The rate-limiting enzyme of the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, provides essential intermediates for the prenylation of nuclear lamins and Ras and dolichol-mediated glycosylation of growth factor receptors. The diterpene geranylgeraniol downregulates the level of HMG CoA reductase and suppresses the growth of human liver, lung, ovary, pancreas, colon, stomach, and blood tumors. We evaluated the growth-suppressive activity of geranylgeraniol in human prostate carcinoma cells. Geranylgeraniol induced dose-dependent suppression of the viability of human DU145 prostate carcinoma cells (IC 50 ¼ 80 AE 18 mmol/L, n ¼ 5) following 72-h incubations in 96-well plates. Cell cycle was arrested at the G1 phase with a concomitant decrease in cyclin D1 protein. Geranylgeraniol-induced apoptosis was detected by flow cytometric analysis, fluorescence microscopy following acridine orange and ethidium bromide dual staining, and caspase-3 activation. Geranylgeraniol-induced viability suppression was accompanied by concentration-dependent decrease in the level of HMG CoA reductase protein. As a nonsterol molecule that downregulates HMG CoA reductase in the presence of sterols, geranylgeraniol may have potential in the chemoprevention and/or therapy of human prostate cancer.
Introduction
The estimated 23,000 isoprenoids are mevalonate-derived products of plant secondary metabolism. 1 Within this class of chemicals are the 'pure' isoprenoids with their entire structure derived from the 5-carbon isoprene unit. The tumor-suppressive activity of dietary pure isoprenoids encompassing the monoterpenes, sesquiterpenes, and diterpenes has been previously reviewed. 2 The tumor-suppressive activity of dietary isoprenoids has been ascribed at least in part to the suppression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity, the rate-limiting activity in the mevalonate pathway. Mevalonate-derived intermediates, most notably farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), are essential for the posttranslational prenylation of Ras and nuclear lamins and dolichol-mediated glycosylation of insulin-like growth factor I (IGF-I) receptor 3 that support growth. Among the pure isoprenoids is the sesquiterpene farnesol 4 shown to downregulate HMG CoA reductase. A more recent study demonstrated that geranylgeraniol is more active than farnesol in inducing reductase degradation in human SV-589 immortalized fibroblasts expressing the SV40 large T antigen 5 ; geranylgeraniol promotes the degradation of reductase following sterol-stimulated ubiquitination. Consequently, geranylgeraniol has been shown to suppress the growth of murine B16 melanoma cells, 6 likely due to the reduced availability of FPP and GGPP. Our recent study showed that supplemental mevalonate, the product of HMG CoA reductase, attenuated geranylgeraniol-mediated growth suppression in murine B16 melanoma cells, further supporting geranylgeraniol-mediated reductase suppression. Nevertheless, the impact of geranylgeraniol on the level of HMG CoA reductase protein has not been shown in a tumor cell line.
In this study we evaluated the effect of geranylgeraniol on cell viability and HMG CoA reductase in human prostate carcinoma cells. Geranylgeraniol induced cell cycle arrest at the G1 phase and initiated apoptosis, effects accompanied by downregulation of HMG CoA reductase level. We chose the prostate cancer cells based on the following considerations. The use of statins, competitive inhibitors of HMG CoA reductase, has been associated with lower risk of prostate cancer. 7, 8 More recently, suppression of HMG CoA reductase and the processing of its transcriptional factor, sterol regulatory element binding protein 2 (SREBP-2), was correlated with reduced viability of human prostate cancer cells, 9 suggesting that HMG CoA reductase may afford a viable target for intervention in prostate cancer.
Materials and methods

Chemicals
Geranylgeraniol was purchased from Sigma-Aldrich (St. Louis, MO, USA). Lovastatin was a gift from Merck Research Laboratories (Rahway, NJ, USA).
Cell viability assay
Human DU145 prostate carcinoma cells (HTB-81, ATCC, Manassas, VA, USA) were grown in Eagle's minimal essential medium (MEM) modified by ATCC to contain 1.0 mmol sodium pyruvate/L, 0.1 mmol nonessential amino acids/L, and 1.5 g sodium bicarbonate/L, supplemented with 10% fetal bovine serum (FBS, Hyclone Laboratories Inc., Logan, UT, USA) and 80 mg gentamycin/L. Cultures of the cells, seeded in 0.1 mL medium with 1000 cells/well in a 96-well plate, were incubated for 24 h at 37 C in a humidified atmosphere of 5% CO 2 . At 24 h the medium was decanted from each well and 0.1 mL fresh medium containing geranylgeraniol was added. All cultures contained 1 mL/L each of ethyl alcohol. Incubation continued for additional 72 h. The 72-h cell populations following a quick rinse with 0.1 mL Hank's balanced salt solution (HBSS) were determined by adding 20 mL of CellTiter 96 Õ Aqueous One Solution to each well; plates were held in the dark at 37 C for 2 h and then read at 490 nm with a SPECTRAmax Õ 190 multi-plate reader with SOFTmax Õ PRO version 3.0 (Molecular Devices, Sunnyvale, CA, USA). Absorbances from wells containing cell-free medium were used as baselines and were deducted from absorbances of other cell-containing wells. The IC 50 value is the concentration of geranylgeraniol required to suppress the net increase in cell number by 50%.
Cell cycle distribution
DU145 cells were seeded in 25 cm 2 flasks (Becton Dickinson Labware, Franklin Lakes, NJ, USA) at 1.5 Â 10 6 cells/flask with 5 mL medium/flask and incubated for 24 h. Medium was then decanted and cultures replenished with medium containing geranylgeraniol that had been dissolved in ethyl alcohol. Following additional 24 -and 48-h incubations, adherent DU145 cells were harvested by trypsinization and pelleted by low-speed centrifugation. Cell pellets were fixed in 1 mL 70% ethanol at À20 C overnight and washed in 1 mL phosphatebuffered saline (PBS). Cells (5 Â 10 5 ) were re-suspended in 500 mL PBS containing 0.5 mg RNAse A (Sigma-Aldrich) and incubated at 37 C for 30 min. Following gentle mixing a 100 mL aliquot of propidium iodide (Sigma-Aldrich, 1 g/L in PBS containing 0.1% Triton X-100) was added. The cells were incubated in the dark at room temperature for 15 min and then held at 4 C in the dark for flow cytometric analysis. 10 Aliquots of 1 Â 10 4 cells were analyzed for DNA content using a BD FACSCaliber TM flow cytometer (BD Biosciences, San Jose, CA, USA). The distribution of cells in the G1, S, and G2/M phases of the cell cycle was determined using MultiCycle AV software (Phoenix Flow Systems, San Diego, CA, USA).
Annexin V assay for apoptosis DU145 cells were seeded in 25 cm 2 flasks (Becton Dickinson Labware) at 1.5 Â 10 6 cells/flask with 5 mL medium/flask and incubated for 24 h. Medium was then decanted and cultures replenished with medium containing geranylgeraniol and lovastatin (pre-dissolved in dimethyl sulfoxide). Following additional 24-h incubation, adherent DU145 cells were harvested by trypsinization, combined with floaters and pelleted by low-speed centrifugation. Resuspended cells in 150 mL medium containing 1 Â 10 4 cells were mixed with 50 mL of the Guava Nexin TM reagent containing Annexin V-PE and Nexin 7-amino-actinomycin D (7-AAD), loaded onto the 96-well plate, and incubated at room temperature in the dark for 20 min. Samples containing 5 Â 10 3 cells were analyzed by using a Guava EasyCyte flow cytometer (Guava Technologies, Inc., Hayward, CA, USA) with the Guava ExpressPlus program. 10, 11 Annexin V is a phospholipid-binding protein that has high affinity for phosphatidylserine 12 translocated from the internal surface to the outer surface of cell membrane at the early stage of apoptosis. 13 7-AAD selectively permeates late stage apoptotic and dead cells. Therefore, cells that are viable (Annexin VÀ and 7-AADÀ), early apoptotic (Annexin Vþ and 7-AADÀ), late apoptotic (Annexin Vþ and 7-AADþ) and dead cells with nuclear debris (Annexin VÀ and 7-AADþ) can be separated and percentages of these cell populations quantified.
Acridine orange and ethidium bromide dual staining assay for apoptosis
Human DU145 prostate carcinoma cells were inoculated in 96-well plates with 2 Â 10 3 cells per well and incubated for 24-h. Medium was then decanted and cultures replenished with medium containing geranylgeraniol and lovastatin. Following additional 24-h incubation, the media was decanted and 100 mL cold PBS was added. A dye mixture (4 mL) containing 50 mg/mL acridine orange (Becton, Dickinson and Company, Sparks, MD, USA) and 50 mg/mL ethidium bromide (Sigma-Aldrich) was added to each well. Following a 2min staining the cells were observed under an Axiovert 200 M microscope (Carl Zeiss MicroImaging Inc., Thornwood, NY, USA) equipped with a FluoArc lamp, an AxioCam MRm digital camera system (Carl Zeiss), and AxioVision Rel. 4.3 program (Carl Zeiss). Representative fields of each well with green and red fluorescence emitted by acridine orange and ethidium bromide staining were captured using fluorescein isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC) filters, respectively. 11
Western blot
Following incubation with geranylgeraniol and lovastatin for 24 and 48 h, human DU145 prostate carcinoma cells were washed with 10 mL ice cold PBS twice and then 150 mL of lysis buffer (50 mmol/L Tris-HCl, pH 8.8, 5 mmol/L EDTA, 1% SDS) containing freshly mixed 1% protease inhibitor cocktail (Sigma-Aldrich) was added to the flask. Cells were sonicated (Fisher Scientific) for 45 s and placed in a dry bath incubator (Boekel Scientific, Feasterville, PA, USA) at 90 C for 20 min.
For analysis of HMG CoA reductase, DU145 cells cultured in 10-cm dishes at 3.5 Â 10 6 per dish were incubated in MEM media containing 10% FBS and 0-100 mmol/L geranylgeraniol. Two additional groups of cells were incubated with MEM media supplemented with 10% lipoprotein deficient serum (LPDS); these cells were treated with either 10 mmol/ L mevalonate in the presence of 1 mg/mL of 25-hydroxycholesterol or 0.05 mmol/L mevalonate only. Following 24-h incubation the cells were scraped and membrane fractions obtained as previously reported. 14 Protein concentration of each sample was determined with BCA TM Protein Assay Kit (Pierce, Rockford, IL, USA). Samples containing 60 mg proteins from whole cell lysates were mixed with Laemmli buffer (Bio-Rad Laboratories, Hercules, CA, USA) at 1:1 ratio (v/v) and boiled for 5 min before being loaded onto a Mini PROTEAN Õ 3 (Bio-Rad) electrophoresis unit with a 15% SDS-polyacrylamide gel. Membrane extracts (20 mg proteins) were mixed with equal volume of buffer (62.5 mmol/L Tris-HCl, pH 6.8, 15% (w/v) SDS, 8 mol/L urea, 10% (v/v) glycerol, and 100 mmol/L dithiothreitol) and 1/6 volume of the 4 Â SDS loading buffer (150 mmol/L Tris-HCl, pH 6.8, 12% (w/v) SDS, 30% glycerol, 6% b-mercaptoethanol, and bromphenol blue) and incubated at 37 C for 20 min prior to loading to an 8% SDS polyacrylamide gel. Western blot with monoclonal antibodies to cyclin D1, procaspase-3 (Cell Signaling Technology, Beverly, MA, USA) and HMG CoA reductase was performed as described previously. 6
Statistics
One-way analysis of variance (ANOVA) and Kruskal-Wallis tests were performed to assess the differences between groups using Prism Õ 4.0 software (GraphPad Software Inc., San Diego, CA). Differences in means were analyzed by Dunnett's multiple comparison test unless specified otherwise. Two-way ANOVA was analyzed by SPSS version 19. Levels of significance were designated as P < 0.05. Figure 1 shows the concentration-dependent suppression of the viability of human DU145 prostate carcinoma cells by geranylgeraniol. Our previous study with murine B16 melanoma cells showed that geranylgeraniol induces cell cycle arrest at the G1 phase. 6 We then evaluated the impact of geranylgeraniol on the cell cycle distribution of the DU145 cells ( Figure 2 ). Following a 24-h incubation with geranylgeraniol the percentage of cells at the G1 phase increased from 50.0 AE 2.0% (control) to 56.7 AE 2.5% (50 mmol/L geranylgeraniol), and 77.0 AE 1.9% (100 mmol/L geranylgeraniol, P < 0.01), respectively. Conversely, the percentage of cells at the S phase decreased from 44.8 AE 3.4% (control) and 44.3 AE 6.2% (50 mmol/L geranylgeraniol), respectively, to 19.5 AE 1.0% (100 mmol/L geranylgeraniol, P < 0.05). Geranylgeraniol also induced G1 arrest in cells following 48h incubation.
Results
The G1 arrest induced by geranylgeraniol was accompanied by suppression of the expression of cyclin D1, a key regulator in the G1/S cell cycle progression. 15 Following 48-h incubations with 100 mmol/L geranylgeraniol, the level of cyclin D1 protein decreased significantly (Figure 3 ).
Previous studies have also shown that geranylgeraniol induces apoptosis in tumor cells, an effect we then evaluated in the DU145 cells using the Guava Nexin TM assay with flow cytometry. Following a 24-h incubation with 0, 50, and 100 mmol/L geranylgeraniol and 10 mmol/L lovastatin, the percentage of viable cells (Figure 4) were 98.2 AE 0.4, 97.9 AE 0.2, 92.6 AE 0.4 (P < 0.01), and 96.1 AE 0.7 (P < 0.01), respectively. Concomitantly, treatment with geranylgeraniol and lovastatin increased the percentage of apoptotic cells. The percentage of early apoptotic cells in cells treated with 100 mmol/L (0.9 AE 0.3, P < 0.05) of geranylgeraniol was significantly higher than that in untreated cells (0.3 AE 0.2). Cells treated with 100 mmol/L geranylgeraniol (6.0 AE 0.6%, P < 0.01) and 10 mmol/L lovastatin (2.8 AE 0.8%, P < 0.01) had significantly higher late apoptosis rate than that of the control cells (1.2 AE 0.4%).
Geranylgeraniol-and lovastatin-induced apoptosis was confirmed by fluorescence microscopy ( Figure 5 ) and procaspase-3 activation ( Figure 6 ). In photomicrographs of DU145 cells ( Figure 5 ) obtained by acridine orange and ethidium bromide dual staining, viable cells have acridine orange staining with normal cell morphology. Acridine orange and ethidium bromide stained cells with condensed nucleus are in early and late apoptosis stages, respectively. 11, 16 The ethidium bromide stained DU145 cells following a 24-h incubation with 50 ( Figure 5(g) ) and 100 ( Figure 5(h) ) mmol/L of geranylgeraniol and 10 ( Figure 5 (i)) and 20 ( Figure 5(j) ) mmol/L of lovastatin were more visible than the control (Figure 5(f) ). Arrows mark the red fluorescence emission from ethidium bromide staining shown in late apoptotic and necrotic cells induced by geranylgeraniol and lovastatin. Following 48-h incubations with 50 and 100 mmol/L geranylgeraniol, the intensity of procaspase-3 decreased in a concentration-dependent manner ( Figure 6 ); 100 mmol/L geranylgeraniol induced procaspase-3 activation at 24-h. There was a concurrent appearance of the lower-molecular weight bands in geranylgeraniol-treated cells, indicating the cleavage of procaspase-3.
Our previous study suggested that geranylgeraniolmediated growth suppression in melanoma cells may stem from the down-regulation of HMG CoA reductase. We then evaluate the impact of geranylgeraniol on the level of HMG CoA reductase in DU145 cells (Figure 7) . Following 24-h incubation in medium supplemented with 10% LPDS, there was a high level of reductase expression due to the lack of sterol feedback inhibition. Mevalonate (10 mmol/L) and 25hydroxycholesterol (1 mg/mL) reduced reductase to an undetectable level, consistent with the notion that sterols and non-sterols accelerate the degradation of reductase. 17 When DU145 cells were grown in medium supplemented with 10% FBS, the reductase level was lower than that in cells grown in medium supplemented with LPDS. Geranylgeraniol at 75 and 100 mmol/L further reduced the level of reductase (P < 0.05).
Discussion
In this study, we have shown for the first time that geranylgeraniol suppresses the viability of human prostate DU145 carcinoma cells. The prostate cancer cells (IC 50 ¼ 80 mmol/L) appear to be more resistant than the murine B16 melanoma cells (IC 50 ¼ 55 mmol/L) we previously evaluated 6 based on the IC 50 values. Nevertheless, this IC 50 value for prostate cancer cells still falls between those determined for human HuH-7 hepatoma cells (IC 50 ¼ 10 mmol/L) 18 and human H460 lung adenocarcinoma cells (IC 50 ¼ 400 mmol/L) 19 that are among a list of tumor cells 6 sensitive to geranylgeraniol-mediated growth suppression.
The geranylgeraniol-mediated cell cycle arrest at the G1 phase and the downregulation of cyclin D1 are reminiscent of the impacts in B16 melanoma cells. 6 These results are consistent with previous findings that mevalonate deprivation induced G1 arrest 20 in human prostate cancer cells, downregulated the expression of cyclin D1, 21 and upregulated the expressions of p21 22, 23 and p27, [22] [23] [24] two proteins involved in regulating G1/S transition. The monoterpenes perillyl alcohol and geraniol and sesquiterpene farnesol also induced G1 arrest and increase in p27 expression. 25 In addition to cell cycle arrest, geranylgeraniol-induced apoptosis also contributed to growth inhibition. 26 and HL60 27 leukemia cells and human HuH-7 hepatoma cells. 18 Inhibition of protein kinase C (PKC), 28 activation of c-Jun N-terminal kinases (JNK), 29 and release of cytochrome c 30 have been implicated in geranylgeraniol-induced apoptosis.
Geranylgeraniol-induced caspase-3 activation is in agreement with previous observations in human U937
These effects of geranylgeraniol on cell viability, cell cycle arrest and apoptosis were concurrent with the downregulation of HMG CoA reductase (Figure 7) . HMG CoA reductase is under a multivalent regulation mediated by sterols and nonsterol isoprenoids. 3 Mevalonate-derived nonsterol isoprenoids have been suggested to accelerate the sterol-stimulated degradation of HMG CoA reductase, an important part of the reductase regulation. In our hands 25-hydroxycholesterol and mevalonate reduced reductase to below minimal detectable level, suggesting that this regulatory mechanism mediated by sterols and nonsterol isoprenoids persists in human prostate cancer cells. Several in vitro and in vivo studies suggested that farnesol is the signal for mammalian HMG CoA reductase degradation. 4, 31, 32 In contrast to studies using Chinese Hamster Ovary (CHO) cells 4 treated with compaction and Met-18b-2 cells 32 with mevinolin showing farnesol as the HMG CoA reductase regulator, others found that a 1000fold increase in rat hepatic farnesol level did not affect the turnover rate of hepatic HMG CoA reductase. 33 In addition, the apparent farnesol-induced reductase degradation may be caused by detergent-insoluble reductase precipitated by farnesol that was not detectable by immunoprecipitation. 4 More recent evidence suggested that geranylgeraniol might be the nonsterol to mediate HMG CoA reductase degradation. Geranylgeraniol (125 mmol/L) suppressed acetate incorporation into cholesterol by 70% in NIH3T3 cells, an effect greater than that induced by a higher concentration (167 mmol/L) of farnesol. 34 Geranylgeraniol was also more potent than farnesol in suppressing HMG CoA reductase in human mevalonate kinase-deficient fibroblasts 35 and human A549 lung carcinoma cells 36 and in inducing HMG CoA reductase degradation, an effect amplified by sterols, in human SV-589 immortalized fibroblasts. 5 In the presence of sterols, reductase is ubiquitinated but not degraded; supplemental geranylgeraniol (10, 30 and 100 mmol/L) and to much less extent farnesol stimulated the extraction of reductase from endoplasmic reticulum and its degradation by the proteasome. 5 It was postulated that geranylgeraniol is converted to GGPP, which is then used to prenylate a G protein such as Rab that is involved in vesicular transport. 37 In CHO cells farnesyl derivatives -farnesyl acetate and ethyl farnesyl ether -caused the degradation of HMG CoA reductase; Bradfute and Simoni 31 postulated that these compounds directly induce the degradation because the mevalonate flux had been inhibited by statins. Later Song et al. 38 showed that lanosterol and 24, 25-dihydrolanosterol, metabolites that accumulated when the farnesyl derivatives inhibited its conversion to cholesterol, accelerated the degradation of HMG CoA reductase. Farnesyl derivatives may have indirectly induced the degradation of HMG CoA reductase through lanosterol and 24, 25-dihydrolanosterol accumulation.
In addition, our quantitative real-time PCR analysis showed no significant changes in the mRNA levels of HMG CoA reductase in DU145 cells following 24-h incubations with 0, 25, 50, 75, and 100 mmol/L of geranylgeraniol (data not shown), suggesting a posttranscriptional downregulation of reductase.
Consistent with geranylgeraniol-mediated downregulation of HMG CoA reductase, geranylgeraniol (IC 50 ¼ 25 mmol/L) was more potent than farnesol (IC 50 ¼ 39 mmol/L) in suppressing the growth of human MIA PaCa-2 pancreatic adenocarcinoma cells. 39 Geranylgeraniol was also a more active apoptosis inducer than farnesol in HL-60 cells 40 and human A549 lung carcinoma cells. 36, 41 Moreover, geranylgeraniol also shares a striking similarity with the competitive inhibitor of HMG CoA reductase, lovastatin, in inducing cell cycle arrest and apoptosis in DU145 cells (Figures 4 and 5 ). This similarity is in accordance with our previous observation that mevalonate attenuated geranylgeraniol-induced growth inhibition in B16 melanoma cells. 6 The activation of PKC, an upregulator of HMG CoA reductase mRNA level, 42 prevents geranylgeraniol-induced apoptosis, 28 lending further support to the role of HMG CoA reductase in mediating the geranylgeraniol action.
The geranylgeraniol-mediated HMG CoA reductase downregulation and apoptosis observed herein present apparent contradictions to reports that geranylgeraniol prevented lovastatin-induced apoptosis in prostate tumor cells 43 and benign prostatic hyperplasia stromal cells. 44 In the latter studies, however, statin-mediated sterol deprivation may have obstructed the role of geranylgeraniol in accelerating steroldependent HMG CoA reductase degradation. 5 As a consequence, the conversion from geranylgeraniol to GGPP 37 filled a void of prenyl protein transferase substrates and prevented apoptosis.
Based on the current results, we propose a working model for geranylgeraniol-mediated growth suppression (Figure 8) . By downregulating the level of HMG CoA reductase, geranylgeraniol downsizes the pools of mevalonate and the downstream farnesyl-and geranylgeranylpyrophosphates; consequently, the prenylation of Ras and nuclear lamins and glycosylation of IGF-I receptor are ablated, impeding cell growth. In vivo studies using models of prostate cancer are warranted to validate the growth-suppressive activity of geranylgeraniol; lack of such studies precludes discussion on the physiological applicability of the concentrations used herein. Nevertheless, gavage feeding of geranylgeraniol to Wistar rats suppressed chemically initiated hepatocarcinogenesis and, more relevant to our study, reduced plasma cholesterol level 45 ; the latter is a potential outcome of HMG CoA reductase downregulation. It remains to be seen whether the synergistic impact of geranylgeraniol and other mevalonate suppressors such as the tocotrienols 6 persists in prostate cancer cells and whether such impact is mediated by downregulation of HMG CoA reductase. Geranylgeraniol may be a new weapon in the arsenal of mevalonate-suppressive isoprenoids in the fight against prostate cancer.
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